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Risk Factors for Venous Thrombosis: Prevalence,
Risk, and Interaction
Fnts R Rosendaal
Annually, 1 in 1,000 individuals is affected by venous
thrombosis Risk factors that are known to increase
the risk of thrombosis may be either genetic or ac-
quired, or have a combmed origin Many of these risk
factors are very frequent, among which several have
been recently identified, such äs resistance to acti-
vated protein C by factor V Leiden, hyperhomocystem-
emia, high levels of factor VIII, äs well äs the classical
acquired risk factors, such äs surgery and malignan-
cies When the prevalence of risk factors is high, it
becomes likely that in some individuals two or more
risk factors will be present simultaneously The ques-
tion "What happens to the risk in these circum-
stances?" is one involving interaction, also known äs
effect modification or synergy In this article we re-
view the prevalence and risk estimates for the various
genetic and acquired risk factors for venous thrombo-
sis, discuss the concept of interaction, and give an
overview of the evidence for interaction of these risk
factors
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ONE OF THE MOST tantahzmg problems mthrombosis research m the last decade has
recently appeared to be an issue of interaction
Since 1981, many famihes with hereditary protein
C deficiency have been reported,24 55 which led to
the conclusion that a heterozygous defect of protein
C brought about a high nsk of thrombosis From
these family studies it also seemed clear that the
abnormahty was uncommon (an estimate was
l 16,000 heterozygous individuals in the popula-
tion23)
Apparently in contradiction, in 1987, Miletich
published the results of screemng for protein C
deficiency among blood donors," which yielded
two surprismg results first, the prevalence of the
defect was estimated at between 0 4% to l 3%, and
second, among these individuals and their deficient
relatives, thrombosis appeared to be uncommon
Instead of a rare and severe disorder, protein C
deficiency appeared to be a common and mild
abnormahty " It was later shown that the types of
mutations leading to protein C deficiency in these
blood donor famihes were not different from those
found m protein C-deficient thrombophilia fami-
]les 115 116 145
In retrospect, however, it became clear that
although in the classical thrombophilic famihes the
thrombosis cosegregated with the defect, the dis-
ease was also frequently found in the family
members who had normal protem C levels, they
expenenced thrombosis far more often than was to
be expected from general population data After
resistance to activated protem C (APC) had been
descnbed äs the most common thrombogemc clot-
ting defect,33 it was shown that among the same
famihes with protein C deficiency of previous
reports, many also carried the factor V Leiden
abnormahty Family members with neither defect
had a low mcidence of thrombosis, äs in the general
population, members with both defects had the
highest nsk, and those with one defect had an
mtermediate riskso This not only showed the
synergistic effect of combmed defects, but also
explamed the apparent discrepancy between the
family studies and the blood donor studies famihes
with thrombophilia are recogmzed because of the
interaction of several defects that are present simul-
taneously m those famihes
Recently, a very similar observation has been
reported for antithrombin deficiency from the West
of Scotland Blood Donor Study96138 among blood
donors with the deficiency and their deficient
relatives, the frequency of thrombotic events was
much lower than has been reported previously for
thrombophilic famihes with antithrombin defi-
ciency
The study of mteractions between nsk factors
has become relevant because it will help explain
the differences m nsks between individuals, and it
has become possible because many nsk factors for
thombosis are now known Interaction is an issue
whenever two or more nsk factors are present
simultaneously, the chances of such an occurrence
depend on the prevalence of the mdividual nsk
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factors In this article we discuss the estabhshed
nsk factors for venous thrombosis with regard to
prevalence and nsks, and subsequently, we review
the available evidence on the mteraction of nsk
factors
VENOUS THROMBOSIS. GENERAL
INTRODUCTION
Venous thrombosis has an overall frequency of
about l in 1,000 mdividuals per year4102 It is
uncommon m young mdividuals and becomes
more frequent with advancmg age 102 Its most
frequent mamfestation is thrombosis of the deep
vems of the leg, which may have senous morbidity
(post-thrombotic syndrome, respiratory msuffi-
ciency due to pulmonary emboli, bleedmg compli-
cations of anticoagulant treatment) and, although
rare, it may cause death due to pulmonary embo-
hsm26142
Classical nsk factors for deep vein thrombosis
(DVT) mclude surgery, immobilization, fractures,
puerperium, paralysis, prolonged bed rest, and use
of oral contraceptives52 85 86 In some instances,
thrombosis appears to be hereditary occumng m
famihes, and often causing thrombosis among
mdividuals m these famihes at a young age and
without apparent cause This tendency to develop
thrombosis has been called thrombophilia, which,
if a genetic explanation is likely, is called heredi-
tary thrombophilia28586 A list of important nsk
factors for venous thrombosis is given in Table l
For most of these risk factors it is known whether
they are acquired or genetic, however, for several,
this is not known or a combmed ongm has been
demonstrated For instance, hyperhomocystem-
emia may be the result of low Vitamin intake or of
defects m the enzymes m methionme metabohsm,
such äs cystathiomne synthase (CS) deficiency or a
recently descnbed genetic vanant in the methylene-
tetrahydrofolate reductase (MTHFR) gene 47
PREVALENCE OF GENETIC ABNORMALITIES
CAUSING THROMBOSIS
Estimates of the prevalence of deficiencies of
protein C, protein S, antithrombin, and of resis-
tance to APC have been denved from three sources
healthy mdividuals, unselected patients with ve-
nous thrombosis, and selected patients with venous
thrombophilia The results of several studies classi-
fied in this way are listed m Table 2
For deficiencies of protein C and antithrombin,
the prevalence has been mvestigated m a study of
almost 10,000 blood donors 138139 This led to
prevalence estimates of l in 500 for protein C
deficiency and l in 5,000 for type I antithrombin
deficiency The findmgs for protein C deficiency
are similar to those of Miletich among more man
5,000 blood donors," who reported a prevalence of
l m 250 mdividuals For protein S deficiency, there
are no studies of sufficient size among healthy
mdividuals to reach an estimate of its prevalence
For APC-resistance and factor V Leiden, the
estimates among Caucasians ränge from 3% to
7%,118122136 whereasit is very uncommon in Asians
andAfncans30"3
Among consecutive patients with objectively
confirmed DVT, deficiencies of protein C, protein
S, and antithrombin combmed are found m about
5% 3983 In 20% of unselected patients with DVT,
APC-resistance is present84122
Among selected patients with venous thrombo-
sis, higher prevalences of abnormahties can be
found The results depend on the selection cnteria
used, these are usually thrombosis at a young age,
recurrent thrombotic events, thrombotic events that
appeared to occur spontaneously, or thrombosis in
Table 1 Risk Factors for Venous Thrombosis
Acquired Inhented Mixed
Age
Previous thrombosis
Immobilization
Major surgery
Orthopedic surgery
Mahgnancy
Oral contraceptives
Hormonal replacementtherapy
Antiphosphohpid syndrome
Myeloproliferative disorders
Polycythemia vera
Antithrombin deficiency
Protein C deficiency
Protein S deficiency
Factor V Leiden (FV R506Q)
Dysfibrmogenemia
Factor II 20210A
Hyperhomocystememia
High factor VIII levels
Highfibrinogen levels
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Table 2. Prevalence of the Major Thrombophilic Clotting Abnormalities (%)
Protein C
Deficiency
Protein S
Deficiency
Antithrombin
Deficiency
APC-
Resistance
Factor II
20210A
Healthy individuals
Scotland (n = 9669)138·'39 0.2*
USA (n = 5422)" 0.4
USA (n = 704)118
Sweden (n = 130)136
Netherlands (n = 474)108·122
Netherlands (n = 100)108
Netherlands (n = 646)
Consecutive patients with first DVT
Netherlands (n = 277)59 3
Netherlands (n = 474)83·108 3*
Netherlands (n = 471)122
Thrombophilic patients
Spain (n = 204)137 1
Germany(n = 158)128 9
Netherlands (n = 113)21 8
Israel (n = 107)9 6
USA (n = 25)54
Netherlands (n = 28)108
1
6
13
3
0.02*t
0.5
5
4
7
20*
52
2.3
1.0
1.2
6.2
17.9
Abbreviation: APC, activated protein C.
*DNAconfirmed.
tType l antithrombin deficiency.
patients with a positive family history. The reported
prevalences among selected patient groups for
deficiencies of protein C, protein S, and antithrom-
bin are mostly between 5% and lo%.9·21·128·137
APC-resistance is found in more than half of all
cases of hereditary thrombophilia, and is the most
important cause of hereditary thrombosis.12·32'33'54·122
The polymorphism in the prothrombin gene
(20210 G to A) that has recently been described108
was found in 6% of unselected patients with
thrombosis and in 18% of patients with familial
thrombophilia. In a group of nearly 500 healthy
individuals, the variant was present in 2%.108 The
polymorphism is associated with increased levels
of prothrombin, which suggests that these are the
effectors of the thrombotic risk.108
PREVALENCE OF ACQUIRED AND MIXED
RISK FACTORS
The prevalence of hyperhomocysteinemia and
high levels of factor VIII depend on the cutoff
values that are used because plasma levels are
continuous variables rather than dichotomous mo-
lecular abnormalities. Here we will use cutoff
values that were also used in the studies that
reported hyperhomocysteinemia and high levels of
factor VIII äs risk factors for venous thrombosis.
As with genetic abnormalities, the prevalences of
high levels may differ between populations.
Homocysteine levels exceeding 18.5 μιηοΙ/L
were found in 5% of the Dutch population and 10%
of an Italian group of healthy individuals.39'133 Den
Heijer found that the risk of venous thrombosis
associated with hyperhomocysteinemia only be-
came apparent when levels exceeded 18 μιηοΙ/L.39
Factor VIILC levels exceeding 150 lU/dL were
observed in 11% of healthy Dutch volunteers.82
These measurements of homocysteine and factor
VIII were all performed only once,39·82·133 so,
although they represent the prevalence in the
general population at a given time, it is unclear how
many individuals have constantly increased levels
and how many have only temporarily increased
levels.
The prevalence of the acquired risk factors, such
äs surgery, immobilization, malignancy, pregnancy,
puerperium, oral contraceptive use, and hormonal
replacement therapy (HRT) all heavily depend on
age; some, notably use of oral contraceptives and
HRT, vary widely between societies.
RISK OF VENOUS THROMBOSIS
Two approaches have been used to assess the
risk of venous thrombosis for individuals with
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genetic clotting abnormalities: first, studies in fam-
ily members of probands with one of these abnor-
malities; and second, population-based studies.
These two types of studies may yield different
information. Family studies are based on selected
families in which the hereditability of the abnormal-
ity has been demonstrated. Typically, in these
studies, the occurrence of thrombosis is compared
between the family members with and without the
clotting factor abnormality while the proband is
excluded from the analysis. Because hereditability
is a prerequisite in studies of this design, these
studies are efficient in qualitatively answering
questions concerning the risks associated with
specific genotypes.
In studies that are based in the population,
quantitative risk estimates can be obtained. In
case-control studies, patients with thrombosis are
compared to healthy individuals with regard to the
prevalence of clotting factor abnormalities. The
odds ratios that result from these studies are
estimates of the relative risks, which indicate how
much higher the risk of thrombosis is in the
presence of a particular risk factor than in the
absence of that factor. Because only individuals are
included and not families, no direct conclusions
about hereditability can follow from these studies.
However, when unselected patients are included in
a population-based study, and compared to appro-
priately chosen controls, the results on a particular
risk factor for thrombosis apply, äs an average risk,
to all individuals with that risk factor in the
population. This is not the case for family studies
because these include families that were recog-
nized and referred because of a conspicuously high
frequency of thrombosis. So, strictly speaking, the
results from the family studies only apply to
families detected in a similar way, for they are
conducted in a selected high-risk stratum of the
population. Many of these selected families with
thrombophilia have more than one thrombophilic
abnormality,80 and therefore the results from family
studies cannot be extrapolated to unselected indi-
viduals, nor vice versa. An individual found to have
a thrombogenic abnormality in a study of healthy
individuals from the general population will most
likely be a carrier of only that one abnormality; if
he is recognized äs proband in a family with
thrombophilia, he may well be a carrier of two or
more defects; if he is an unselected patient with
thrombosis, he may be either.
The dominant effect of selection on the apparent
severity of disease can also be shown by looking at
the age of onset.88 In families selected because of
familial thrombophilia, the first thrombosis oc-
curred around the age of 30 years for individuals
with protein C deficiency and factor V Leiden
alike. In unselected patients with thrombosis and
these same abnormalities, the age at which throm-
bosis occurred was 45 years, again without any
difference according to the type of defect.88 This
implies that if patient groups are compared that
have been selected with slightly different criteria,
differences in clinical severity may be observed
that are the result of the selection criteria and not of
true differences in severity.
Protein C Deficiency
Many families with hereditary protein C defi-
ciency have been reported since 198l.18'24·55 Hetero-
zygous protein C deficiency increases the risk of
thrombosis without any apparent difference accord-
ing to type of deficiency (type I, low plasma level;
and type II, functional defect) or to the underlying
mutation. "5 DVT of the leg is the most common
manifestation, although thrombosis may occur at a
variety of other sites.3·58·110
Family studies have shown that family members
who are protein C-deficient have an 8- to 10-fold
increased risk of venous thrombosis; by the age of
40 years, about half of them will have experienced
at least one thrombotic event.3·18 In these families,
many thrombotic events occur spontaneously, ie,
without any obvious cause.65
The relative risk of 6.5 obtained from a popula-
tion-based study is very similar to this result from
family studies.83 The prevalence of protein C
deficiency äs found in unselected patients with a
first thrombotic event (3%)59·83 and healthy individu-
als from the general population (0.2%)139 is in
accordance with a relative risk of this magnitude.
Protein S Deficiency
Families with protein S deficiency and venous
thrombosis have been reported since 1984.22·130
Whereas the clinical Symptoms are similar to those
found in protein C deficiency,43 it is not clear
whether the different types of protein S deficiency
that have been described (type I, low plasma
concentrations of total and free protein S; type II,
functional defect; type III, low free protein S) lead
to similar risks of thrombosis. Type I and type III
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protein S deficiency have recently been reported to
be phenotypic variations of the same genotype.156
The mutations in the protein S gene have been
reported to be associated with protein S defi-
ciency.1-107·129
The prevalence of protein S deficiency in the
general population is unknown and estimates of
incidence rates in families are lacking, so the risk of
thrombosis associated with protein S deficiency has
not been quantitated. In a population-based case-
control study, no relation between protein S defi-
ciency and thrombosis could be established.83 Al-
though the numerous reports on protein S-deficient
kindreds support an increased risk of venous throm-
bosis, the evidence is much less solid than for
protein C deficiency, and the risks are not known
quantitatively.
Antithrombin Deficiency
Since 1965 numerous families with antithrombin
deficiency have been reported.37·41·63·141 The clinical
Symptoms of antithrombin deficiency closely re-
semble those of protein C and protein S deficiency,
although superficial thrombophlebitis seems to oc-
cur less often.2 A large number of mutations
associated with antithrombin deficiency have been
described.87 Type I (low levels in plasma) and type
II (functional defect) are both associated with
thrombophilia; type IIc, however, only causes a
severe form of thrombophilia in the homozygous
individual.
Antithrombin deficiency appears to be more
severe than deficiencies of protein C and protein S.
Thrombosis may occur at a young age, even earlier
than 16 years, and about half the patients suffer a
first thrombotic event before age 25.63·141 The
50-fold difference between prevalence among pa-
tients with a first event of DVT and prevalence in a
healthy population59·83'138 Supports a higher throm-
botic risk in antithrombin deficiency than in protein
C deficiency. In a direct comparison in a population-
based study, however, such a difference was not
found.83
APC Resistance
Resistance to APC was first described by Dahl-
bäck in 1993.33 The defect is associated with an
abnormality in clotting factor V,34 and this mutation
(factor V R506Q, factor V Leiden)1' appears respon-
sible for the large majority of cases of APC
resistance.12·157 APC resistance is far more common
than the other forms of hereditary thrombophilia
(Table 2).
In a family study, the risk of thrombosis was
clearly higher in family members who were APC-
resistant than in those who were not.136 Approxi-
mately 25% of the patients with APC resistance had
suffered thrombosis before the age of 50 years.136
This risk is lower than the figures reported for
families with protein C deficiency,3 which may
indicate a lower thrombotic risk associated with
APC resistance than with protein C deficiency. The
discrepancy may also be the result of selection bias
(in the protein C-deficient families). Because APC
resistance is common, families with APC resistance
may not have been äs heavily selected on the
severity of thrombophilia äs families with protein C
deficiency in previous studies.88 The relative risk
associated with APC resistance observed in a
population-based case-control study did not differ
from that found for protein C deficiency (relative
risk of 7 for APC resistance, and 6.5 for protein C
deficiency), which suggests that the two abnormali-
ties do not differ in severity.83·84
Factor II20210 G — A
The prevalence of this variant was 6.2% in
consecutive patients with thrombosis and 2.3% in
healthy control subjects, which yielded a relative
risk of 2.8 for carriers of the variant versus
noncarriers.108 This implies that this is a relatively
frequent risk factor, which confers less of a risk
than deficiencies of protein C, protein S, antithrom-
bin, or factor V Leiden. The allele frequency was
determined among 474 healthy subjects, and it has
a considerable statistical uncertainty (95%-confi-
dence interval of the prevalence of carriers l .0% to
3.6%). In a group of 100 healthy volunteers, 1%
carried the A-allele, and in a second large sample of
more than 600 healthy men from Leiden, 1.2%
carriers were observed (Doggen CJ, personal com-
munication, March 1997). If the prevalence in the
population is around 1% rather than the 2% ob-
served in the Leiden Thrombophilia Study, the
relative risk might be higher (for a prevalence of
1%, it would be 6, ie, similar to that of the other
hereditary defects leading to thrombophilia). The
polymorphism is closely related to factor II levels,
which in turn are associated with the risk of
thrombosis (Table 3). A factor II level exceeding
115 lU/dL increases the risk of DVT twofold.108
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Table 3. Prothrombin Levels, Prothrombin Genotype, and
Risk of Thrombosis
„ , , . „ , Prevalenceof 20210 A GenotypePlasma Prothrombin Relative
Level (lU/dL)
<95
95-104
104-115
>115
Risk(OR)
1
1.3
1.4
2.2
Patients (%)
0
2.8
6.9
18.2
Controls (%)
0
0
1.7
9.3
Abbreviation: OR, odds ratio.
Results are given for 424 patients and 474 controls for whom
DNA was available and who were not on oral anticoagulant
treatment.108
Hyperhomocysteinemia
In two case-control studies, hyperhomocystein-
emia has been shown to increase the risk of
D VT.39·133 In both studies, a 2.5-fold increased risk
was found for levels exceeding 18.5 μιηοΙ/L, and a
three- to fourfold increased risk for levels exceed-
ing 20 μιηοΙ/L. Among patients with juvenile
thrombosis, a high prevalence of hyperhomocystein-
emia has been reported,44·45 which was most appar-
ent on post-methionine loading homocysteine mea-
surements (the studies by Simioni133 and den
Heijer39 were based on fasting homocysteine mea-
surements). Among patients with a first episode of
venous thrombosis before age 40, Falcon found
19% with hyperhomocysteinemia.44 From this study
we can infer a more than 10-fold increased relative
risk because among healthy young individuals the
abnormality is rare. This higher relative risk in the
younger age groups could not be confirmed in the
Dutch study.39 Hyperhomocysteinemia has also
been shown to increase the risk of recurrent throm-
botic events.38
Hyperhomocysteinemia may be the result of
several underlying abnormalities, genetic äs well äs
environmental. Of the latter, low vitamin intake
(notably vitamins B6, B12, and folic acid) are the
most common.72'"4'146 Heterozygous carriership of
CS deficiency, the abnormality that in the homozy-
gous form causes classic homocystinuria,100 is an
infrequent genetic cause. Far more common is the
recently described variant of the MTHFR gene that
leads to a thermolabile variant of this enzyme and
to mildly increased levels of homocysteine.42·47'73·79
Surprisingly, homozygous carriership of this vari-
ant is not associated with an increased risk of
venous thrombosis.5'78'"1·117 It is difficult to recon-
cile these fmdings with those of an increased risk of
venous thrombosis caused by hyperhomocystein-
emia. It may be that the homocysteine levels with
this variant are not sufficiently increased to cause
thrombosis, or that hyperhomocysteinemia itself
will not lead to thrombosis unless, for instance,
folate levels are normal. Finally, because genotypes
are invariant whereas homocysteine levels can be
affected by other risk factors, it cannot be ruled out
that hyperhomocysteinemia is a marker of either
disease or risk factor Status rather than a cause of
disease.78 Nevertheless, hyperhomocysteinemia is
important in the etiology of thrombosis because no
less than 5% in the Dutch and 10% in the Italian
control group of healthy individuals had levels over
18.5 μιηοΙ/L, which were associated with an in-
creased risk.39'133
High Levels of Factor VIII
Factor VIII levels exceeding 150 lU/dL are
associated with a sixfold increased risk äs com-
pared to levels below 100 IU/dL.82 Because blood
group and von Willebrand factor (vWF) are strong
determinants of the factor VIII concentration, these
are also risk factors for DVT: individuals with
non-O blood groups have a twofold increased risk
compared to subjects with other ABO blood groups,
and persons with vWF levels exceeding 150 IU/dL
have a threefold increased risk compared to those
with levels less than 100 IU/dL. The effect of blood
group has been known since the 1970s, and,
interestingly, has also been observed for arterial
vascular disease.77·97·102·121·140 However, blood group
and vWF levels are only risk factors because they
affect the factor VIII level, which implies that the
risk will not be increased in an individual with
non-O blood group or high vWF levels if the factor
VIII concentration is normal.82 These findings82
were based on measurements after the thrombotic
event, which includes the possibility of post-hoc
increases in factor VIII:C. Recently, O'Donnell has
shown that among patients with thrombosis, the
high factor VIII levels are likely to be based on
increased factor VIII synthesis, and are not associ-
ated with signs of acute phase reaction.l04
High factor VIII levels are very frequent and the
relative risk is high, which implies that high factor
VIII levels are among the most important causes of
thrombosis. For factor VIII levels exceeding 150
IU/dL, which are found in 11 % of the population
and which increase the risk 6-fold,82 the population
attributable risk is 35%. This indicates that (assum-
ing a causal relation) 35% of all events of DVT in
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the population can be attributed to high factor VIII
levels (for protein C deficiency, this is only 3%).
Oral Contraceptives and Other Hormonal Steroids
The thrombogenicity of the pill has been known
since 1961 when Jordan reported pulmonary embo-
lism in a nurse who had just started oral contracep-
tion.71 Since then, numerous reports in the 1960s
and 1970s have confirmed that oral contraceptives
increase the risk of venous äs well äs arterial
thrombosis.I26>I3S The early oral contraceptives con-
tained a high level of estrogen (100 μg and more),
which over the decades has been decreased to
reduce the risk of thrombosis. The evidence that
this has in fact led to a reduction of the risk of
venous thrombosis is scarce. The early case-control
studies in the 1960s found relative risks for idio-
pathic DVT ranging from 4 to 8.68·125-150 In the
1970s, a large case-control study found a relative
risk of 11l6 in users versus nonusers, and a prospec-
tive cohort study reported a relative risk of 4.124 A
prospective study in the 1980s found a relative risk
of 7.109 In the most recent studies in the 1990s, the
risks reported are not substantially different from
the early reports. In the international World Health
Organization (WHO) study,154 oral contraceptives
were associated with a 4.2-fold increased risk; in
the Transnational study with a fourfold increased
risk134; whereas in the Leiden Thrombophilia Study
the age-adjusted relative risk was 6.149 In the latter
study, the risk conferred by oral contraceptives
with 30 μg ethinylestradiol and 50 μg ethinylestra-
diol was the same.13 In another report, however,
oral contraceptives containing 50 μ% ethinylestra-
diol or more appeared to confer a higher risk than
those containing less than 50 μg.50 Similar dose-
related results have been reported from Sweden.17
It has been argued that the finding of a decreasing
rate of thrombosis with lower estrogen dose was
biased by differences in diagnostic methods for
DVT and age differences between women using
different formulations.76
Even if the risk of venous thrombosis has
decreased with lower estrogen content, it is clear
that this has not been a dramatic decrease and that
the risk of venous thrombosis is still present with
the current low-dose formulations. There are no
data concerning the newest oral contraceptives
containing less than 30 μg ethinylestradiol, there-
fore, claims regarding their superior safety are
unfounded. Possibly the most convincing evidence
that it is unjustified to assume an ever-decreasing
risk of thrombosis with decreasing amounts of
estrogen has come from the reports on hormonal
replacement therapy. These contain an amount of
estrogen that is equivalent to about 5 μg of estra-
diol,26 ie, a very low dose compared to oral
contraceptives, and still were found to increase the
risk of venous thromboembolism 2.1- to 3.6-
fold.35·56·69 When investigated in healthy volun-
teers, the effects on the hemostatic System of oral
contraceptives containing either 30 or 50 pg ethinyl-
estradiol did not differ.127 The thrombogenicity of
oral contraceptives is not necessarily partly or
completely mediated by the hemostatic system and
alternative hypotheses, eg, an immunologic re-
sponse to estrogens, have been proposed for which
a dose-related risk is not even plausible.8
Because oral contraceptives are used by young
women among whom the incidence of thrombosis
is low, the absolute risk brought about by use of
oral contraceptives remains low: from approxi-
mately l per 10,000 women per year to 4 per
10,000 women per year.149 On the other hand,
because oral contraceptives are widely used, they
are the most important cause of thrombosis in
young women.
Recently, several studies have shown that it is
not just the estrogen component in oral contracep-
tives that is responsible for the risk of venous
thrombosis: preparations containing a so-called
third-generation progestogen (desogestrel, ges-
todene) lead to a twofold higher risk of thrombosis
than products containing a second-generation pro-
gestogen (mostly levonorgestrel).13'70·134·153 Be-
tween the various studies, extensive adjustment for
possible confounders, eg, age, family history, fac-
tor V Leiden carriership, duration of use, previous
pregnancy, and obesity, did not alter the findings. It
has subsequently been shown that mortality from
venous thromboembolism has increased among
young women in the United Kingdom and the
Netherlands since the mid-1980s, since oral contra-
ceptives with third-generation progestogens have
been increasingly in use.143·148
Pregnancy and Puerperium
The estimates of the incidence of thrombosis in
pregnancy and puerperium vary widely. In two
large series, thrombosis in pregnancy was found in
0.13 per l ,000 women75 and 0.7 per l ,000 women,144
which translates into incidence rates of 0.17 to 0.93
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per 1,000 (pregnant) women-years. These inci-
dence rates are lower than the overall incidence
rates for venous thrombosis; this is, however, the
result of pregnant women being younger than the
general population. Among women aged less than
30, Nordström found an incidence of 0.075 per
1,000 women-years, which is clearly lower than the
rates reported in pregnancy.102 In the Leiden Throm-
bophilia Study, pregnancy was associated with a
fourfold increased risk of venous thrombosis.81
The thrombotic risk is greater in puerperium than
in pregnancy. Per 1,000 birth-giving women, it is
estimated that 2.3 to 6. l75·144 will experience throm-
bosis postpartum. This indicates that a pregnant
women has a three to five times higher chance of
developing thrombosis shortly after than during
pregnancy; and also, because the postpartum period
is much shorter than the pregnancy, that the "throm-
bogenicity" of the postpartum period is much
higher than that of pregnancy (20- to 30-fold higher
incidence rate).
Surgery and Trauma
The risk of thrombosis is greatly increased
during surgery, mostly during orthopedic surgery
and neurosurgery. In hip and knee surgery, äs well
äs major hip and knee trauma, the risk of thrombo-
sis reaches 30% to 50%.28·64·67·103 The risk is also
high, up to 30%, in abdominal surgery, gynecologic
surgery, and urologic surgery (especially open
prostatectomy).10'95·101·151 The risk of thrombosis is
increased in all forms of major injury,48 with risk
estimates of 54% in patients with major head
injury, 62% of patients with spinal injury, 61% of
patients with pelvic fractures, 80% of patients with
femoral fractures, and 77% of patients with tibial
fractures.48
Malignant and Other Diseases
Patients with malignancies have an increased
incidence of venous thrombosis. In a population-
based study in urban Sweden, which included 366
patients with a first or recurrent DVT, 19% of the
patients had a malignancy known at the time of the
diagnosis of thrombosis, and an additional 5% were
diagnosed with malignancy in the year after the
thrombosis diagnosis.102 These figures obviously
exceed the expected prevalence of malignancies in
a control group of individuals without thrombosis.
An approximation of the relative risk of thrombosis
brought about by malignancies was reached by
following patients with and without DVT after
(positive and negative) testing for thrombosis.51
The relative risk was several-fold increased and
very high in those aged younger than 50 (relative
risk, 19). The risk of thrombosis is particularly high
in (mucin-producing) adenocarcinomas, eg, gastric
carcinoma and pancreatic carcinoma.
Other medical conditions predisposing to throm-
bosis are those associated with immobilization,
particularly paralysis152; cardiac disease94; myelo-
proliferative disorders27; and antiphospholipid anti-
bodies (lupus anticoagulant or anticardiolipin anti-
bodies).66·89
THE CONCEPT OF INTERACTION
Interaction, also known äs effect modification or
synergism, is present when the risk in the presence
of two risk factors exceeds the sum of the separate
effects of the two factors.123 Stated differently,
effect modification is present when a certain risk
factor has a different effect in the presence of
another factor than in the absence of that factor. So,
under an interactive effect, more people with a
combination of risk factors develop the disease
than would be expected based on the disease
incidences for the risk factors when present sepa-
rately.91 This does not necessarily imply any knowl-
edge of the mechanism of action of the risk factors,
or of their combination, nor does the presence of
interaction indicate common mechanisms.131
Table 4 shows a hypothetical example. When the
background incidence is l per 1,000 (per unit of
time), A adds one patient to this background risk.
When only B is present, the number of diseased
individuals increases from one to three, ie, B adds
two. The expected number of patients for the
combination of A and B is therefore one (back-
ground), plus one (A), plus two (B), which is 4 per
1,000. The expected incidence of 4 per 1,000 when
there is no interaction is associated with a risk
difference of 3 per 1,000 (compared to the category
without A and B) and a relative risk of 4.
Here we will use this model for interaction and
Table 4. Concepts of Interaction
Risk
Factor A
-
+
-
+
Risk
Factor B Incidence
1/1000
2/1000
+ 3/1000
+ 7
Risk
Difference
0*
1/1000
2/1000
?
Relative
Risk
1*
2
3
7
*Reference category.
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define departures from additivity äs an indication
for interaction. Several additional arguments for
this defmition and a technical discussion are given
in the Appendix.
GENE-GENE INTERACTION
Homozygous Defects
Double defects in the same gene are a first
example of so-called gene-gene interaction. Pa-
tients homozygous for protein C deficiency have
been reported.19 Because the allele frequency of
protein C deficiency is low, the patient with a
double defect is rare and may often be the result of
consanguinity. In these patients protein C activity
in plasma is absent or very low, and the thrombotic
tendency is usually very high, with severe thrombo-
sis (purpura fulminans) developing shortly after
birth.19 Homozygous protein S deficiency has also
been reported, and while extremely rare, it appears
äs severe äs homozygous protein C deficiency.92
Homozygous antithrombin deficiency is extremely
rare and probably incompatible with life: two
siblings with homozygous antithrombin deficiency
died within 3 weeks after birth.57 Antithrombin
type II heparin-binding site deficiency only leads to
increased thrombotic risk in the homozygous form.
Because of its high allele frequency, homozy-
gous camers of the factor V Leiden are more
common. The homozygous abnormality appears
much less severe than homozygous protein C
deficiency and several of the homozygous patients
have remained thrombosis-free well into adult
ljfe 53,122 stjU5 me j-jgj, Of homozygous carriership is
10-fold greater than that of heterozygous carrier-
ship, and 90-fold greater compared to individuals
without the mutation. Also, these individuals expe-
rience thrombosis at a younger age than those with
heterozygous factor V Leiden.122 The majority of
symptomatic factor V Leiden homozygous patients
are women; therefore, it seems likely that the
estimate of a 90-fold greater risk is partly the result
of interaction with sex, and specifically the use of
oral contraceptives.122·149 This may indicate a less
extreme increased risk in men who are homozy-
gous carriers of factor V Leiden or in women who
do not use oral contraceptives.
Very high levels of homocysteine are found in
homocystinuria, first described in the 1960s.25·49
Because of a homozygous deficiency of CS, which
catabolizes homocysteine to cystathionine, the lev-
els of homocysteine become so high that homocys-
teine is excreted in the urine.100 This classical form
of homocystinuria is a severe inborn error of
metabolism, which is associated with mental retar-
dation, skeletal abnormalities, ectopia lentis, and
arterial vascular disease äs well äs venous thrombo-
sis. The prevalence is l in 335,000 live births."4
With regard to venous thrombosis—and the same
holds true for arterial disease—the risk appears
much higher in homocystinuria than in hyperhomo-
cysteinemia, although not äs devastatingly high äs
in homozygous protein C deficiency.
Because homocysteine may be metabolized via
two pathways, of which the vitamin B6-dependent
transsulfuration by CS to cysteine is one, and the
vitamin B12 and folic acid-dependent remethyl-
ation to methionine by methionine synthase is the
other, hyperhomocysteinemia may be the result of
defects in either of the pathways—or in the vita-
mins that are involved äs coenzymes. Whereas
homocystinuria is the result of a homozygous
defect in the transsulfuration of homocysteine,
heterozygous CS deficiency is rarely the cause of
hyperhomocysteinemia: more often mildly in-
creased homocysteine levels are the result of poor
remethylation due to either low intake of folic acid
and vitamin B|2, or to genetic defects in this
pathway. A recently described variant of the en-
zyme MTHFR is a very common abnormality
leading to increased levels of homocysteine due to
inadequate remethylation.42·47·79 The variant is pre-
sent in homozygous form in about 10% of the
general population.78 Several studies,5'78'"1'"7 al-
though not all,6 report that carriership of this
variant in the homozygous form, although associ-
ated with increased homocysteine levels, does not
affect the risk of venous thrombosis. The variant
leads to a reduction of 50% of the normal activity
of MTHFR73·114; when the enzyme activity is
absent, äs in homozygous MTHFR deficiency, a
severe homocystinuria is the result. This form
accounts for about 10% of homocystinuria, and
thus is even more rare than homozygous CS
deficiency.
Combined Genetic Defects
Combinations of deficiencies of protein C, pro-
tein S, and antithrombin have been reported, but are
extremely rare due to the low allelic frequency of
each of these defects (and also because consanguin-
ity will not lead to an increased frequency of these
combinations äs it will for the homozygous form of
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each of the individual deficiencies). Factor V
Leiden is common, however, and combinations
with deficiencies of protein C, protein S, and
antithrombin have been described. Although ana-
lyzed in a variety of ways, the reports on combined
defects all indicate a higher risk for the combined
defect than for the single defect, which, however, is
not so high äs the risk for homozygous protein C or
protein S deficiency. In thrombophilic families in
which protein C deficiency and factor V Leiden are
both present, a history of thrombosis was present in
31% of individuals with protein C deficiency only,
in 13% of individuals with factor V Leiden only,
and in 73% of individuals with both defects (analy-
sis among sibships in which both defects were
segregating).80 In families with thrombophilia with
antithrombin deficiency, the risk of a combination
of this defect with factor V Leiden was even higher:
whereas 57% of individuals with only antithrombin
deficiency had a history of venous thrombosis, and
20% of those with factor V Leiden only, 11 of the
12 camers of both defects (92%) had suffered
venous thrombosis.147 In families with thrombo-
philia and protein S deficiency, the risk of thrombo-
sis was also higher in those with a combined defect,
ie, protein S deficiency and factor V Leiden, than in
those with either of the two defects.7'155
In all these instances of more than one defect, ie,
the homozygous abnormalities, and the combina-
tion of several defects in the natural coagulation
Inhibition mechanisms, the available data do not
allow an evaluation of interaction with the concept
outlined above. Because the results are reported äs
age-of-onset, or prevalence of a history of thrombo-
sis, and more importantly, because the families
were often selected on the presence of one of the
defects, it is not possible to examine if the inci-
dence of thrombosis in the presence of two defects
exceeds the sum of the incidences of each of the
two defects separately. In fact, little more can be
concluded than that the risk for combined defects in
the natural clotting inhibitors is higher than for
single defects. For homozygous protein C or pro-
tein S deficiency the risk becomes nearly absolute.
All studies on combinations of two different defects
in the natural clotting Inhibition pathways (mostly
combinations of factor V Leiden with a deficiency
of either antithrombin, protein C, or protein S)
report very high risks of ever experiencing throm-
bosis. It should be indicated, however, that all these
studies were performed in highly selected families,
and it cannot be ruled out that these families may
have other yet unknown thrombogenic defects.
GENE-ENVIRONMENT INTERACTION
Interaction is most readily observed, and also
most relevant, for risk factors with a high preva-
lence and therefore has a high probability of being
present simultaneously in one individual. Risk
factors that have such a high prevalence are sur-
gery, immobilization, pregnancy and puerperium,
use of sex steroids (oral contraceptives, HRT) for
the acquired risk factors, and factor V Leiden,
hyperhomocysteinemia, and high levels of factor
VIII for the endogenous risk factors. Several of the
possible interactions between these factors have
been studied.
Hyperhomocysteinemia and Factor V Leiden
It is unclear if hyperhomocysteinemia and factor
V Leiden have synergistic effects. Mandel, in a
study of 45 individuals from seven families with
(homozygous) homocystinuria, found venous
thrombosis to be associated with hyperhomocystein-
emia only in individuals who were also carriers of
factor V Leiden.93 This observation suggests a
strong interaction, in which factor V Leiden is a
prerequisite for the thrombogenic effect of hyperho-
mocysteinemia. The interaction is not absolute,
however, because other homozygous CS deficient
homocystinuric patients have been reported to
suffer venous thrombosis while free of factor V
Leiden (or deficiencies of protein C, protein S, and
antithrombin).112 For mild hyperhomocysteinemia,
there can be little doubt that it is associated with an
increased risk of thrombosis also in the majority of
individuals free of factor V Leiden.31·39 It is unclear
if there is a synergistic effect in those with com-
bined hyperhomocysteinemia and factor V Leiden.
In the Leiden Thrombophilia Study, isolated hyper-
homocysteinemia and isolated factor V Leiden
each increased the risk of thrombosis, indicating
that neither factor is required for the other factor to
have an effect; the risk when both factors were
present did not exceed these separate risks, ie, there
was no sign of interaction.39 The distribution of the
abnormalities over a mixture of cases with arterial
or venous occlusive disease reported by D'Angelo31
suggests a more than additive effect when re-
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evaluated äs a case-case analysis.74 Within the
Physicians' Health Study, the risk for the combined
abnormalities also exceeded the risk for factor V
Leiden and hyperhomocysteinemia alone."9 It is
difficult to reach a conclusion from these widely
varying results: a relative risk of only 2.0 for the
combined defect (äs compared to individuals with
neither factor V Leiden nor hyperhomocystein-
emia) in the Dutch study,39 and 21.8 in the Ameri-
can study"9 (both using a 95th percentile cutoff
point for hyperhomocysteinemia). One explanation
may be the wide statistical uncertainty resulting
from the small number of individuals with the
combined defect in these studies. A clue for a
biological explanation may be that the Leiden
Thrombophilia Study39 included all patients with
thrombosis, of all ages, whereas in the other series
the results concerned young patients,31 or were
most striking for idiopathic thrombosis.119
Oral Contraceptives and Thrombophilic Defects
Oral contraceptives lead to a high risk of throm-
bosis in deficiencies of natural anticoagulant pro-
teins, especially in antithrombin deficiency, with an
estimated incidence of 27% per year.106 For factor
V Leiden, the interaction with oral contraceptives
has been shown in a population-based case-control
study, ie, in consecutive patients with thrombosis
(Table 5).l49
As Table 5 shows, the risk of thrombosis in users
of oral contraceptives who are carriers of the factor
V Leiden mutation exceeds the sum of the separate
effects of these two risk factors.149 In a subsequent
analysis, this interaction was most striking for oral
contraceptives containing a third-generation proges-
togen.13
Among homozygous carriers of the factor V
Leiden mutation there is a preponderance of women
among symptomatic patients, the majority of whom
have used oral contraceptives.120'122 In a series of
Table 5. Factor V Leiden and Oral Contraceptives: Single and
Combined Effects
Factor V Oral Relative Incidence per 10,000
Leiden Contraceptives Risk Women per Year
1.0*
+ 3.7
+ - 6.9
+ + 34.7
0.8
3.0
5.7
28.5
*Reference category.
homozygous patients, 80% of the women with
thrombosis had been using oral contraceptives.120
Pregnancy, Puerperium, and Thrombophilic
Defects
In women from families with familial thrombo-
philia due to deficiencies of protein C, protein S, or
antithrombin, or due to factor V Leiden, the risk of
thrombosis in pregnancy and puerperium is ex-
tremely high, with estimates ranging from 10% to
more than 40%.29'36·61 The risk is highest in anti-
thrombin deficiency, whereas for protein S defi-
ciency the risk during pregnancy does not appear to
be increased. These risk estimates indicate a syner-
gistic effect but may largely be restricted to women
from selected families with thrombophilia. In a
recent study of female relatives of probands with
thrombophilia, in which the proband was excluded
from the analysis, the overall risk of pregnancy-
associated thrombosis (pregnancy and puerperium)
was 4.1% in women with antithrombin, protein C,
or protein S deficiency.46 Although substantially
less than the previous estimates, this is still much
higher than the risk in nondeficient women.
Deficiencies of protein C, protein S, and anti-
thrombin are rare, and therefore even a highly
increased risk of thrombosis in pregnancy will only
concern a fraction of all pregnancies. This is
different for the much more common factor V
Leiden. Among women with thrombosis during
pregnancy, 20% to 60% proved to be APC-resistant
in subsequent investigations.15'60·62
Antiphospholipid Antibodies and Factor V Leiden
Antiphospholipid antibodies are a common cause
of thrombosis,14 and therefore a combination of this
abnormality with factor V Leiden carriership may
be encountered. Although it has been shown that
factor V Leiden carriership is not a prerequisite for
the occurrence of thrombosis in the antiphospho-
lipid syndrome,40 the simultaneous presence of
both abnormalities in one patient may lead to a
severe thrombotic tendency.20 In a series of 78
women with a history of thrombosis, the combina-
tion of anticardiolipin antibodies or lupus anticoagu-
lant and resistance to APC was found in 22%,
which suggests a strong synergistic effect.l4 Similar
results have been observed by others.105·132
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Factor V Leiden and Malignancies
Because malignancies are often the underlying
disease in thrombosis, it is important to know if the
thrombotic risk is modified in the presence of APC
resistance. In one article, it is reported that among
patients with malignancies, carriers of the factor V
Leiden mutation had a fivefold increased risk.98
Given the high risk brought about by malignancies,
this indicates a synergistic effect.
Surgery and Thrombophilic Defects
The overall frequency of thrombotic comphca-
tions in surgery in individuals with deficiencies of
protein C, protein S, or antithrombin has been
estimated at about 20%.36 It is unclear whether
surgery in factor V Leiden carriers has a different
thrombotic risk from surgery in other individuals.
From the Leiden Thrombophilia Study, no interac-
tion of more than an additive nature was apparent.8'
It may well be that surgery is such a strong risk
factor for venous thrombosis, that the simultaneous
presence of other nsk factors loses its importance.
It should be noted, however, that the issue is
confounded by the use of anticoagulant prophy-
laxis for many surgical interventions.
CONCLUSION
When a risk factor is established äs such, it can
be said that it increases the risk by a certain
amount, or that it increases the probability of
disease in those exposed to that factor äs compared
to those not exposed to it. The prior probabilities of
disease are higher in those with the risk factor than
in those without it. Some individuals who were
exposed, however, will not experience thrombosis,
and some who were not exposed will. So, in
retrospect, each individual either increases his prior
probability to unity, or decreases it to zero. It may
be argued that the differences between these real
events, and the prior probabilities, are all the result
of interaction: among those with a specific overall
or average nsk of disease, there are subgroups with
a much higher risk, and subgroups with a much
lower nsk. The factors that discriminate between
these subgroups are the factors that lead to interac-
tion.
Future research will be aimed at further elucidat-
ing interactive effects because this will help to
pinpoint an individual's risk of thrombosis, and
give insights into the biological mechanisms under-
lying thrombosis.
APPENDIX
The nsk brought about by a factor can be expressed in
absolute and relative terms, le, äs the difference of the disease
frequencies m the presence or absence of the risk factor
(incidence rate difference, or risk difference) or äs the ratio of
these two frequencies (incidence rate ratio or relative nsk) This
has led to the concepts of additivity and multiplicativity Under
an additive model, interaction is said to be present when the
combmed effect of two factors exceeds the sum of the separate
effects in terms of incidence rates, le, risk differences Under a
multiplicative model, the expected effect is defined multiplica-
tively based on incidence ratios, le, relative nsks, and interaction
is considered present when the combmed effect exceeds the
product of the two relative nsks This is shown in a hypothetical
example m Table 4
In an additive model, the expected incidence of disease for the
combmed presence of nsk factors A and B m Table 4 is 4/1,000,
the sum of the disease mcidences of the separate effects The nsk
difference, always m reference to those with neither of the risk
factors, is 3/1,000 In this way, the effect of factor A is to add one
case of disease in the absence of factor B (from 1/1,000 to
2/1,000) äs well äs m the presence of factor B (from 3/1,000 to
4/1,000) If the combmed effect differs from this expected
incidence of 4/1,000, interaction is considered to be present
In a multiplicative model, the expected effect (of no interac-
tion) is denved from the relative nsks factor A doubles the nsk
m the absence of factor B (from 1/1,000 to 2/1,000), and is
therefore also expected to double the risk m the presence of
factor B (from 3/1,000 to 6/1,000) Therefore, under a multipli-
cative model, interaction is considered to be present when the
combmed effect exceeds, or more generally differs from, the
expected frequency of 6/1,000
It is obvious from this example that when nsk differences are
constant, äs m an additive model, relative nsks will not be
constant in the example of Table 4, when the combmed effect of
A and B has an incidence of 4/1,000 (and thus an overall relative
risk of the combination of 4), A will have a relative risk of 2 m
the absence of B, and of l 25 m the presence of B Conversely,
when relative nsks are constant, äs assumed under a multiplica-
tive model, nsk differences will not be constant when factor A
doubles the risk regardless of the absence or presence of factor B
(and therefore factor B tnples the risk regardless of the presence
or absence of factor A), factor A will add l/l ,000 m the absence
of factor B, and 3/1,000 m the presence of factor B
Many techniques that are used to estimate the effect of risk
factors, especially the ones used for multivanate analysis such
äs calculation of the Mantel-Haenszel odds ratio or the use of
logistic regression, assume multiplicativity of nsk factors There
are several reasons, however, to prefer a definition of departure
from additivity äs a sign of interaction MacMahon and Tncho-
poulos state that compansons of effects in additive models are
mtuitively more appeahng, and more relevant for pubhc health
pohcies90 The first argument is that, whereas it may be
computationally convement m regression models to assume
multiplicativity, there is no biologically plausible reason why
nsk factors should multiply one another The second pubhc
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health argument is that when we say that the effect of a usk
factor is constant when its relative nsk is constant, we will call
very different effects the same Foi mstance, if a factor doubles
the nsk of thrombosis for each age class, this may be considered
neghgible m the very young among whom thrombosis is
extremely rare, but may lead to a large numberof excess cases of
thrombosis m older mdividuals, among whom thrombosis is
prevalent
Rothman even takes the view that the additive model, bemg
the parsimomous one, will have the closest association with the
underlymg disease mechamsm, and asserts that departures from
additivity indicate mteraction on the basic cellular or biochemi-
cal level 121
A final argument to use departures from additivity äs the yard
stick for mteraction is that it conforms to the view of the
individual patient "What is my nsk of developmg disease9"
Obviously, the patient will be mterested in the absolute nsk of
disease, and not the relative nsk, and so will his or her doctor
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